<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00620503</url>
  </required_header>
  <id_info>
    <org_study_id>ZP-002</org_study_id>
    <nct_id>NCT00620503</nct_id>
  </id_info>
  <brief_title>Proellex® Pharmacokinetic Bridging Study II</brief_title>
  <acronym>PK</acronym>
  <official_title>Proellex® Pharmacokinetic Bridging Study II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, randomized, single-center, outpatient, unblinded, single-dose, three-way
      crossover study of the safety and PK properties of Proellex® in women ages 18 - 34 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized, single-center, outpatient, unblinded, single-dose,
      three-way crossover study of the safety and PK properties of Proellex® in women ages 18 - 34
      years. Twelve female subjects will each receive a single dose of Proellex®: 25 mg (fed state,
      formulation A), 25 mg (fed state, formulation B), and 25 mg (fasting state, formulation B);
      successive dosing will be separated by at least one week intervals from the previous dosing.
      Blood will be collected prior to taking the dose, and following the dose for 24 hours
      post-dose. Subjects will be discharged from the study after the last blood sample is obtained
      after the third dose of Proellex®. Safety will be assessed throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 29, 2008</start_date>
  <completion_date type="Actual">April 30, 2008</completion_date>
  <primary_completion_date type="Actual">April 30, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Proellex</measure>
    <time_frame>24 hours</time_frame>
    <description>Maximum observed concentration (Cmax) of a single dose of Proellex® (25 mg) Formulation A using two different formulations of the drug in healthy adult female subjects with or without fasting</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-last of Proellex</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Area under the plasma concentration curve from time 0 (AUC0-last) to the last measurable plasma concentration time point, up to 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>24 hours</time_frame>
    <description>Time to maximum plasma occurrence of Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-infinity of Proellex</measure>
    <time_frame>24 hours</time_frame>
    <description>Area under the plasma concentration curve from time 0 to extrapolated to infinity, calculated by summing the area under the curve from time zero to the time of the last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-life (T1/2) of Proellex</measure>
    <time_frame>24 hours</time_frame>
    <description>Time to maximum plasma occurrence of T1/2, calculated as ln(2)/Elimination rate constant.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Formulation A Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Proellex 25 mg formulation A, fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation B Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Proellex 25 mg formulation B, fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation B Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Proellex 25 mg formulation B, fasted</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proellex 25 mg formulation A</intervention_name>
    <description>One Proellex 25 mg formulation A capsule</description>
    <arm_group_label>Formulation A Fed</arm_group_label>
    <other_name>Telapristonee acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proellex 25 mg formulation B</intervention_name>
    <description>One 25 mg Proellex capsule formulation B administered both fed and fasted</description>
    <arm_group_label>Formulation B Fasted</arm_group_label>
    <arm_group_label>Formulation B Fed</arm_group_label>
    <other_name>Telapristone acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be able to speak, read and understand English and be willing and able to
             provide written informed consent on an Institutional Review Board (IRB)-approved form
             prior to the initiation of any study procedures. Subject must have signed and dated a
             written Informed Consent Form (ICF) before undergoing any study related activities,
             including discontinuation of any prohibited medications

          -  Premenopausal women aged 18 - 34 inclusive with body mass index between 18 and 35
             inclusive

          -  Women of child-bearing potential must be willing to use effective non-hormonal,
             double-barrier method contraception during the study period and for a minimum of 30
             days after discontinuation of the study medication. Women who have had a hysterectomy
             will be allowed into the study

          -  Must have a negative urine pregnancy test at screening

          -  Able to swallow gelatin capsules

          -  In general good health

          -  Must have agreed to not attempt to become pregnant at any time during study
             participation or for 30 days thereafter

          -  Must not have used tobacco (nicotine products) for at least two years before the study
             starts

          -  Must have normal (or abnormal and clinically insignificant) laboratory values at
             screening

          -  Willing to remain in the clinic for the screening visit and for the treatment visits

          -  Available for all treatment and follow-up visits

          -  Willing to comply with all study procedures

          -  Additional inclusion criteria may apply

        Exclusion Criteria:

          -  Pregnant or lactating females or women who are attempting or expecting to become
             pregnant at any time during the study

          -  Past or present history of experiencing any allergic reaction to the formulations
             administered in this study, or in the opinion of the Principal Investigator, suggests
             an increased potential for an adverse hypersensitivity

          -  Any medical condition, which, in the judgment of the Principal Investigator, will
             prevent the subject from starting and/or completing the study

          -  Past or present history of any significant cardiovascular, renal, hepatic disease,
             thrombophlebitis, thromboembolic disorders, or cerebrovascular accident requiring
             ongoing medical therapy or clinical intervention

          -  A QTc interval of &gt;450ms at screening

          -  Subject with abnormal screening visit vital signs or clinical laboratory evaluation
             considered clinically significant by the Principal Investigator

          -  Subjects with symptomatic uterine fibroids or endometriosis

          -  Use of other oral contraceptives or hormonal treatments within 30 days of first dose
             of study medication

          -  Use of a hormone-releasing intrauterine device

          -  Subject with a history of alcohol and/or drug abuse

          -  Known active infection of HIV, Hepatitis A, B or C

          -  Subject who has participated in a clinical trial with investigational medication
             within 30 days prior to study medication administration or who plans to take an
             experimental drug prior to the end of 30 days after participation in this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Chan</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Healthcare Discoveries Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 4, 2008</study_first_submitted>
  <study_first_submitted_qc>February 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <results_first_submitted>June 27, 2014</results_first_submitted>
  <results_first_submitted_qc>June 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 21, 2019</results_first_posted>
  <last_update_submitted>June 20, 2019</last_update_submitted>
  <last_update_submitted_qc>June 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PK</keyword>
  <keyword>Pharmacokinetics</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TP1: Fed A, TP2: Fasting B, TP3:Fed B</title>
          <description>Three different treatments of Proellex 25 mg, given in a randomized treatment sequence.
Proellex 25 mg capsule, Formulation A, fed state.
Proellex 25 mg Formulation B, fed state.
Proellex 25 mg Formulation B, fasting state.</description>
        </group>
        <group group_id="P2">
          <title>TP1: Fed B, TP2: Fed A, TP3: Fasting B</title>
          <description>Three different treatments of Proellex 25 mg, given in a randomized treatment sequence.
Proellex 25 mg capsule, Formulation A, fed state.
Proellex 25 mg Formulation B, fed state.
Proellex 25 mg Formulation B, fasting state.</description>
        </group>
        <group group_id="P3">
          <title>TP1: Fasting B, TP2: Fed B, TP3: Fed A</title>
          <description>Three different treatments of Proellex 25 mg, given in a randomized treatment sequence.
Proellex 25 mg capsule, Formulation A, fed state.
Proellex 25 mg Formulation B, fed state.
Proellex 25 mg Formulation B, fasting state.</description>
        </group>
        <group group_id="P4">
          <title>TP1: Fed A, TP2: Fed B, TP3: Fasting B</title>
          <description>Three different treatments of Proellex 25 mg, given in a randomized treatment sequence.
Proellex 25 mg capsule, Formulation A, fed state.
Proellex 25 mg Formulation B, fed state.
Proellex 25 mg Formulation B, fasting state.</description>
        </group>
        <group group_id="P5">
          <title>TP1: Fasting B, TP2: Fed A, TP3: Fed B</title>
          <description>Three different treatments of Proellex 25 mg, given in a randomized treatment sequence.
Proellex 25 mg capsule, Formulation A, fed state.
Proellex 25 mg Formulation B, fed state.
Proellex 25 mg Formulation B, fasting state.</description>
        </group>
        <group group_id="P6">
          <title>TP1: Fed B, TP2: Fasting B, TP3: Fed A</title>
          <description>Three different treatments of Proellex 25 mg, given in a randomized treatment sequence.
Proellex 25 mg capsule, Formulation A, fed state.
Proellex 25 mg Formulation B, fed state.
Proellex 25 mg Formulation B, fasting state.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Screening (up to 21 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 1 (TP1) (7days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (at Least 1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2 (TP2) (7days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (at Least 1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 3 (TP3) (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow-up (up to 14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All 12 participants in the Safety population are included in the Intent-to-Treat (ITT) population.</population>
      <group_list>
        <group group_id="B1">
          <title>25 mg Proellex</title>
          <description>Three different treatments of Proellex 25 mg, given in a randomized treatment sequence.
Proellex 25 mg capsule, Formulation A, fed state.
Proellex 25 mg Formulation B, fed state.
Proellex 25 mg Formulation B, fasting state.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Proellex</title>
        <description>Maximum observed concentration (Cmax) of a single dose of Proellex® (25 mg) Formulation A using two different formulations of the drug in healthy adult female subjects with or without fasting</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Formulation A Fed</title>
            <description>Single dose of Proellex 25 mg formulation A, fed</description>
          </group>
          <group group_id="O2">
            <title>Formulation B Fed</title>
            <description>Single dose of Proellex 25 mg formulation B, fed</description>
          </group>
          <group group_id="O3">
            <title>Formulation B Fasted</title>
            <description>Single dose of Proellex 25 mg formulation B, fasted</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Proellex</title>
          <description>Maximum observed concentration (Cmax) of a single dose of Proellex® (25 mg) Formulation A using two different formulations of the drug in healthy adult female subjects with or without fasting</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405.5" spread="168.2"/>
                    <measurement group_id="O2" value="426.7" spread="158.0"/>
                    <measurement group_id="O3" value="824.2" spread="351.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-last of Proellex</title>
        <description>Area under the plasma concentration curve from time 0 (AUC0-last) to the last measurable plasma concentration time point, up to 24 hours.</description>
        <time_frame>Up to 24 hours</time_frame>
        <population>ITT and Safety populations are the same</population>
        <group_list>
          <group group_id="O1">
            <title>Formulation A Fed</title>
            <description>Single dose of Proellex 25 mg formulation A, fed</description>
          </group>
          <group group_id="O2">
            <title>Formulation B Fed</title>
            <description>Single dose of Proellex 25 mg formulation B, fed</description>
          </group>
          <group group_id="O3">
            <title>Formulation B Fasted</title>
            <description>Single dose of Proellex 25 mg formulation B, fasted</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-last of Proellex</title>
          <description>Area under the plasma concentration curve from time 0 (AUC0-last) to the last measurable plasma concentration time point, up to 24 hours.</description>
          <population>ITT and Safety populations are the same</population>
          <units>ng/mL*hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6851.5" spread="5686.2"/>
                    <measurement group_id="O2" value="7967.9" spread="7125.9"/>
                    <measurement group_id="O3" value="6161.8" spread="4364.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax</title>
        <description>Time to maximum plasma occurrence of Cmax</description>
        <time_frame>24 hours</time_frame>
        <population>All 12 participants in the Safety population are included in the Intent-to-Treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Formulation A Fed</title>
            <description>Single dose of Proellex 25 mg formulation A, fed</description>
          </group>
          <group group_id="O2">
            <title>Formulation B Fed</title>
            <description>Single dose of Proellex 25 mg formulation B, fed</description>
          </group>
          <group group_id="O3">
            <title>Formulation B Fasted</title>
            <description>Single dose of Proellex 25 mg formulation B, fasted</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time to maximum plasma occurrence of Cmax</description>
          <population>All 12 participants in the Safety population are included in the Intent-to-Treat (ITT) population.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="1.2"/>
                    <measurement group_id="O2" value="2.9" spread="1.2"/>
                    <measurement group_id="O3" value="1.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-infinity of Proellex</title>
        <description>Area under the plasma concentration curve from time 0 to extrapolated to infinity, calculated by summing the area under the curve from time zero to the time of the last quantifiable concentration</description>
        <time_frame>24 hours</time_frame>
        <population>All 12 participants in the Safety population are included in the Intent-to-Treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Formulation A Fed</title>
            <description>Single dose of Proellex 25 mg formulation A, fed</description>
          </group>
          <group group_id="O2">
            <title>Formulation B Fed</title>
            <description>Single dose of Proellex 25 mg formulation B, fed</description>
          </group>
          <group group_id="O3">
            <title>Formulation B Fasted</title>
            <description>Single dose of Proellex 25 mg formulation B, fasted</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-infinity of Proellex</title>
          <description>Area under the plasma concentration curve from time 0 to extrapolated to infinity, calculated by summing the area under the curve from time zero to the time of the last quantifiable concentration</description>
          <population>All 12 participants in the Safety population are included in the Intent-to-Treat (ITT) population.</population>
          <units>ng/mL*hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6851.5" spread="5686.2"/>
                    <measurement group_id="O2" value="7967.9" spread="7125.9"/>
                    <measurement group_id="O3" value="6554.0" spread="4350.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Half-life (T1/2) of Proellex</title>
        <description>Time to maximum plasma occurrence of T1/2, calculated as ln(2)/Elimination rate constant.</description>
        <time_frame>24 hours</time_frame>
        <population>All 12 participants in the Safety population are included in the Intent-to-Treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Formulation A Fed</title>
            <description>Single dose of Proellex 25 mg formulation A, fed</description>
          </group>
          <group group_id="O2">
            <title>Formulation B Fed</title>
            <description>Single dose of Proellex 25 mg formulation B, fed</description>
          </group>
          <group group_id="O3">
            <title>Formulation B Fasted</title>
            <description>Single dose of Proellex 25 mg formulation B, fasted</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (T1/2) of Proellex</title>
          <description>Time to maximum plasma occurrence of T1/2, calculated as ln(2)/Elimination rate constant.</description>
          <population>All 12 participants in the Safety population are included in the Intent-to-Treat (ITT) population.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="14.8"/>
                    <measurement group_id="O2" value="27.3" spread="20.7"/>
                    <measurement group_id="O3" value="19.2" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Dose of Proellex 25 mg Formulation A, Fed</title>
          <description>Formulation A: One Proellex 25 mg formulation A capsule, Fed</description>
        </group>
        <group group_id="E2">
          <title>Single Dose of Proellex 25 mg Formulation B, Fed</title>
          <description>formulation B: One 25 mg Proellex capsule formulation B administered both fed and fasted.</description>
        </group>
        <group group_id="E3">
          <title>Single Dose of Proellex 25 mg Formulation B, Fasted</title>
          <description>Formulation B: One 25 mg Proellex capsule formulation B administered both fed and fasted</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>GI cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Emotional lability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstruation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor’s Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor’s Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Repros Therapeutics Inc, an Allergan Affiliate</organization>
      <phone>714-246-4500</phone>
      <email>IR-CTRegistration@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

